Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glargine insulin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Glargine insulin | DRUG | - |
1. Inclusion Criteria 1. CFRD with fasting hyperglycemia (fasting plasma glucose ≥126 mg/dl) 1. . The diagnosis must be made at a time when the patient is in his/her basal state of health with no evidence of acute exacerbation in the preceding two months. a). Acute exacerbation ...
Glargine insulin is being studied for the treatment of cystic fibrosis related diabetes, a form of diabetes that develops in people with cystic fibrosis. It is a long-acting insulin product developed by Sanofi, and the company has evaluated it in a Phase 3 clinical trial in this indication.
Glargine insulin works as an agonist at the insulin receptor, known as INSR. By activating this receptor, it produces a prolonged, relatively steady glucose-lowering effect intended to mimic the body's baseline insulin supply. This contrasts with short-acting insulins given around meals.
Glargine insulin is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical program evaluating the drug in cystic fibrosis related diabetes.
Glargine insulin is in Phase 3 development for cystic fibrosis related diabetes. It is an investigational use of the drug in this specific patient population, and the Phase 3 trial in this indication has been completed.
Glargine insulin has been studied in the Phase 3 trial NCT00222521, titled Insulin Glargine Vs Standard Insulin Therapy. That completed study enrolled 20 participants with cystic fibrosis related diabetes in the United States, including patients aged 12 years and older, and it was randomized but not double blinded.